[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

@jy201506 just a random dude

just a random dude posts on X about $482m, $iova, $12b, $850m the most. They currently have XXX followers and X posts still getting attention that total XX engagements in the last XX hours.

Engagements: XX #

• X Week XXXXX +1,585%
• X Month XXXXXX -XX%

Mentions: X #

• X Week X -XX%
• X Month XX -XX%

Followers: XXX #

• X Week XXX +2%
• X Month XXX +21%

CreatorRank: undefined #

Social Influence

Social topic influence $482m 50%, $iova 50%, $12b 50%, $850m 25%, $350m 25%, if you 25%, niche XX%

Top accounts mentioned or mentioned by @semodough @oldgoldhawkeye

Top assets mentioned Iovance Biotherapeutics, Inc. Common Stock (IOVA)

Top Social Posts

Top posts by engagements in the last XX hours

"i model much higher operating expenses than Truist's $482M number yet see $IOVA become profitable in 2028 much earlier than 2034 by Truist. My key assumptions are 1) 2L NSCLC launch in 2028 and 2) GM reach XX% in 2028. this would lead to a combined product rev of $1.2B operating expense of $850M operation income of $350M in 2028. I bet Truist gave zero credit in 2L NSCLC. If you believe $IOVA's story in 2L NSCLC then it would be a good buy here. Otherwise you should sell"
X Link 2025-12-05T15:18Z XXX followers, 1857 engagements

"basically if one views $IOVA as a niche melanoma company its only modest upside doesnt justify its risk. If one believes $IOVA as a post-PD-1 era IO platform play with potential in multiple solid tumor indications including NSCLC the bet here is highly asymmetric favoring the upside"
X Link 2025-12-05T16:11Z XXX followers, 1250 engagements